

Wako Product Update

| INDEX | |
|--|-----------|
| A. Inhibitors | 3 |
| B. Cancer Research | 4 |
| 1. Metastasis Suppressing Agent | |
| 2. Alkylating Compounds | |
| 3. Antimetabolic Drugs | |
| 4. Antibiotics | |
| 5. Plant Alkaloid | |
| 6. Synthetic Hormone Agents | |
| 7. Platinum Complex | |
| 8. Immunostimulant | |
| 9. Others | |
| C. Research for Biological Defense Mechanism | 6 |
| 1. Lipopolysaccharides (LPS) | |
| D. Cell Culture | 7 |
| 1. Recombinant Proteins Expressed in Plants | |
| E. Research for Signaling Cascade/Glutamate Receptor Substances | 8 |
| F. LabAssay™ - Biochemical Test Kits | 10 |
| G. Epigenetics | 13 |
| 1. DNA Methylation | |
| (1) Inhibitors | |
| (2) Detection of Cell Proliferation | |
| (3) Modified Nucleotides | |
| (4) Others | |
| 2. Cell Cycle and Transcription | |
| (1) HDAC Inhibitors | |
| (2) SIRT1 Activators | |
| H. Environmentally-Sensitive Fluorophore | 16 |
| 1. I-SO-IAA | |
| Alphabetical Index | 2 |

Please visit the Wako Online Catalog
<http://www.e-reagent.com>

Wako

| page | Description |
|----------|---|
| A | |
| 5 | Aclarubicin Hydrochloride |
| 5 | Actinomycin D |
| 10 | Labassay™ A/G |
| 7 | Albumin, Human, recombinant expressed in plant |
| 4 | Alkylating Compounds |
| 10 | Labassay™ ALP |
| 8 | (±)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid |
| 8 | DL-2-Amino-5-phosphonovaleric Acid |
| 8 | AMPA |
| 9 | AMPA/Kainate receptor antagonist |
| 9 | AMPA, Metabotropic receptor group1 (mGlu1, mGlu5) agonist |
| 8 | AMPA receptor agonist |
| 8 | AMPA receptor antagonist |
| 5 | Antibiotics |
| 4 | Antimetabolic Drugs |
| 3 | Apoptosis Inhibitor |
| 14 | Anti 5-Methylcytosine, Monoclonal Antibody |
| 7 | Aprotinin, Bovine, recombinant expressed in plant, Solution |
| 13 | 5-Azacytidine |
| 13 | 5-Aza-2'-deoxycytidine |
| B | |
| 6 | Bestatin |
| 10 | Biochemical Test Kit |
| 5 | Bleomycin Hydrochloride |
| 13 | 5-Bromo-2'-deoxyuridine |
| 4 | Busulfan |
| 4 | 1,4-Butanediol Dimethanesulfonate |
| 15 | Butein |
| C | |
| 4 | Cancer Research |
| 6 | Carboplatin |
| 4 | Carmofur |
| 14 | Cell Cycle and Transcription |
| 3 | Cell Cycle Inhibitor |
| 5 | Chlormadinone Acetate |
| 6 | Cisplatin |
| 8 | CNQX Disodium Salt n-Hydrate |
| 10 | LabAssay™ Creatinin |
| 4 | Cyclophosphamide Monohydrate |
| 8 | D-Cycloserine |
| 4 | Cytarabine |
| 4 | Cytosine-1-beta-D(+)-arabinofuranoside |
| D | |
| 4 | Dacarbazine |
| 5 | Daunorubicin Hydrochloride |
| 14 | 2'-Deoxyinosine 5'-Triphosphate Solution |
| 5 | Dexamethasone |
| 8 | Dextromethorphan Hydrobromide Monohydrate |
| 8 | DL-APS |
| 8 | DL-3,5-DHPG |
| 8 | DL-α-(3,5-Dihydroxyphenyl)glycine |
| 9 | Dizocilpine Maleate |
| 14 | diTP Solution |
| 14 | dm6ATP Solution |
| 14 | dm4CTP Solution |
| 14 | dm5CTP Solution |
| 13 | DNA Methylation |
| 13 | DNA Methyltransferase Inhibitor |
| 8 | DNQX |
| 4 | Doxifluridine |
| 5 | Doxorubicin Hydrochloride |

| page | Description |
|----------|--|
| E | |
| 3 | Environmentally-sensitive Fluorophore |
| 13 | (-)-Epigallocatechin Gallate |
| 13 | Epigenetics |
| 5 | Epirubicin Hydrochloride |
| 3 | ETB |
| F | |
| 4 | 5-Fluorouracil |
| 5 | Flutamide |
| 5 | Fumagillin |
| G | |
| 10 | LabAssay™ Glucose |
| 8 | D-Glutamic Acid |
| 8 | L-Glutamic Acid |
| 8 | DL-Glutamic Acid Monohydrate |
| 8 | Glycine |
| H | |
| 14 | HDAC Inhibitors |
| 14 | HMdCTP Solution |
| 3 | HSP60 Inhibitor |
| 4 | Hydroxycarbamide |
| 14 | 5-Hydroxymethyl-2'-deoxycytidine 5'-Triphosphate Solution |
| 4 | Hydroxyurea |
| I | |
| 8 | (±)-Ibotenic Acid |
| 8 | Ifenprodil Tartrate |
| 4 | Ifosfamide |
| 6 | Immunostimulant |
| 16 | I-SO-IAA |
| 14 | ITSA1 |
| J | |
| 8 | Joro Spider Toxin JSTX-3 |
| K | |
| 8 | Kainate receptor agonist |
| 8 | Kainic Acid n-Hydrate |
| L | |
| 10 | Labassay™ A/G |
| 10 | Labassay™ ALP |
| 10 | LabAssay™ - Biochemical Test Kits |
| 10 | LabAssay™ Creatinin |
| 10 | LabAssay™ Glucose |
| 10 | LabAssay™ Triglyceride |
| 10 | Labassay™ Uric Acid |
| 7 | Lactoferrin, Human, recombinant Expressed in plant |
| 6 | Lipopolysaccharide, from <i>E. coli</i> , by phenol extraction |
| 6 | Lipopolysaccharide, from <i>E. coli</i> , by ultracentrifugation |
| 6 | Lipopolysaccharide, from <i>Proteus vulgaris</i> , by phenol extraction |
| 6 | LPS |
| 7 | Lysozyme, Human, recombinant expressed in plant |
| M | |
| 14 | M 344 |
| 14 | MC 1293 |
| 9 | (±)-MCPG |
| 5 | Medroxyprogesterone Acetate |
| 4 | Melphalan |
| 4 | 6-Mercaptopurine Monohydrate |
| 8 | Metabotropic receptor group1 (mGlu1, mGlu5) agonist |
| 8 | Metabotropic receptor group1 (mGlu1, mGlu5), group2(mGlu2, mGlu3) antagonist |
| 8 | Metabotropic receptor mGlu5 Non-competitive antagonist |
| 4 | Metastasis Inhibitor-22 |
| 4 | Metastasis Suppressing Agent |
| 4 | Methotrexate |
| 9 | N-Methyl-D-aspartic Acid |
| 14 | N6-Methyl-2'-deoxyadenosine 5'-Triphosphate Solution |
| 14 | 5-Methyl-2'-deoxycytidine 5'-Triphosphate Solution |
| 14 | N4-Methyl-2'-deoxycytidine 5'-Triphosphate Solution |
| 9 | 2-Methyl-6-(Phenylethynyl)pyridone Hydrochloride |

| page | Description |
|----------|--|
| M | |
| 4 | MI-22 |
| 14 | Micrococcal Nuclease |
| 5 | Mitomycin C |
| 5 | Mitomycin C with Sodium Chloride |
| 9 | (+)-MK801 Maleate |
| 9 | MPEP Hydrochloride |
| N | |
| 9 | NBQX |
| 9 | NMDA |
| 8 | NMDA, Metabotropic receptor agonist |
| 8 | NMDA receptor agonist |
| 8 | NMDA receptor antagonist |
| 8 | NMDA receptor glycine site agonist |
| 9 | NMDA receptor polyamine site agonist |
| 8 | NMDA receptor polyamine site antagonist |
| 8 | Non-competitive NMDA receptor antagonist |
| 14 | Micrococcal Nuclease |
| O | |
| 6 | Oxaliplatin |
| P | |
| 5 | Paclitaxel |
| 5 | Peplomycin Sulfate |
| 15 | Piceatannol |
| 5 | Pirarubicin |
| 5 | Plant Alkaloid |
| 6 | Platinum Complex |
| 5 | Prednisolone |
| 13 | Procaine Hydrochloride |
| 4 | Procarbazine Hydrochloride |
| 3 | Protein Synthesis Inhibitor |
| Q | |
| 9 | Quisqualic Acid |
| R | |
| 7 | Recombinant bovine proteins expressed in plants |
| 7 | Recombinant human bovine proteins expressed in plants |
| 6 | Research for Biological Defense Mechanism |
| 8 | Research for Signaling Cascade/Glutamate Receptor Substances |
| 15 | Resveratrol |
| 6 | all-trans-Retinoic Acid |
| 3 | Reveromycin A Sodium Salt |
| 3 | RKTS-33 |
| S | |
| 9 | D-Serine |
| 15 | SIRT1 Activators |
| 15 | Sirtinol |
| 16 | Solvent-sensitive Fluorescent Probe |
| 9 | Spermidine |
| 9 | Spermine |
| 15 | Splitomicin |
| 5 | Synthetic Hormone Agents |
| T | |
| 5 | Tamoxifen Citrate |
| 4 | Tegafur |
| 4 | 1-(2-Tetrahydrofuryl)-5-fluorouracil |
| 6 | Tretinoin |
| 15 | Trichostatin A |
| 10 | LabAssay™ Triglyceride |
| 3 | Tryprostatin A |
| 7 | Trypsin, Bovine, recombinant expressed in Corn |
| U | |
| 10 | Labassay™ Uric Acid |
| V | |
| 15 | Valproic Acid |
| 5 | Vinblastine Sulfate |
| 5 | Vindesine Sulfate |
| 5 | Vinorelbine Ditartrate |
| Z | |
| 13 | Zebularine |


Novel Inhibitors

Wako commercialized new inhibitors which were discovered by Dr. Hiroyuki Osada, Antibiotics laboratory of Institute of Physical and Chemical Research (RIKEN) under license from RIKEN.

• HSP60 Inhibitor

ETB

This product is a derivative of epolactaene isolated from *Penicillium*. It has a more potent cytostatic effect on human neuroblastoma cells SH-SY 5Y than that of epolactaene, and induces apoptosis. Furthermore, it has been revealed that ETB induces apoptosis in human T-lymphoma cells Jurkat. Recently, HSP60 was identified as one of ETB binding proteins. ETB binds to HSP60 to inhibit chaperone activity.



[Reference]


Nagumo, Y., Kakeya, H., Shoji, M., Hayashi, Y., Dohmae, N. and Osada, H.: *Biochem. J.*: **387**(3), 835 (2005).

• Protein Synthesis Inhibitor

Reveromycin A Sodium Salt

This product is an antibiotic isolated from *Streptomyces*. It targets isoleucyl-tRNA synthetase and inhibits protein synthesis in eukaryotes. It has been investigated for its antitumor and antifungal activities. However, recent studies have revealed that low-dose of reveromycin A induces cell death of activated osteoclasts, which leads to acidic environment. Thus it receives attention as a candidate for the treatment of osteoporosis/ multiple myeloma.

(This product is a sodium salt of the compound shown right.)




[Reference]

Woo, J. T., Kawatani, M., Kato, M., Shinki, T., Yonezawa, T., Kanoh, N., Nakagawa, H., Takami, M., Lee, K.H., Stern, P.H., Nagai, K. and Osada, H.: *Proc. Natl. Acad. Sci. USA*: **103**(12), 4729 (2006).

• Apoptosis Inhibitor

RKTS-33

This product is a derivative of epoxylohexenone isolated from *Paecilomyces*. It has lower toxicity than epoxylohexenone. Like epoxylohexenone, it inhibits apoptosis not by inhibition of perforin-dependent pathway by cytotoxic T lymphocytes but by selective inhibition of Fas ligand-dependent pathway alone.




[Reference]

Mitsui, T., Miyake, Y., Kakeya, H., Hayashi, Y., Osada, H. and Kataoka, T.: *Biosci. Biotechnol. Biochem.*: **69**(10), 1923 (2005).

• Cell Cycle Inhibitor

Tryprostatin A

This product is an alkaloid antibiotic isolated from *Aspergillus*. It affects the microtubule-associated protein binding site and exhibits antitumor activity by inhibition of cell cycle progression in the M phase specifically



[Reference]

Usui, T., Kondoh, M., Cui, C.B., Mayumi, T. and Osada, H.: *Biochem. J.*: **333**(3), 543 (1998).


| | Description | Wako Cat. No. (Pkg. Size) | Grade | Storage |
|-----------------------------|----------------------------------|---------------------------|-----------------|-------------------------|
| GSP60 Inhibitor | ETB | 051-07671 (200 μ L) | for Cellbiology | Ship and keep at -20 °C |
| Protein Synthesis Inhibitor | Reveromycin A Sodium Salt | 185-02181 (500 μ g) | | |
| Apoptosis Inhibitor | RKTS-33 | 182-02191 (200 μ g) | | |
| Cell Cycle Inhibitor | Tryprostatin A | 203-16961 (500 μ g) | | |

**Coming
Soon!**

1. Metastasis Suppressing Agent

Recent studies have shown that the expression of connexin 26, a protein component of gap junction, is increased in cancer cell lines, and suggested that the protein is involved in the mechanism of metastasis in cancer cells.

It has been revealed that MI-22 (metastasis inhibitor-22), which is a derivative of oleamide, does not only inhibit the connexin 26-mediated formation of gap junction between cancer and other cells but inhibits the spontaneous metastasis *in vivo*.




[Features]

1. Specific inhibition of connexin 26
2. Inhibition of gap junction intercellular communication
3. Inhibition of spontaneous metastasis *in vivo*

[References]

1. Ito, A., et al.; *J. Clin. Invest.*, **105**, 1189 (2000).
2. Ito, A., et al.; *Carcinogenesis*, **25**, 2015 (2004).
3. Ohba, Y., et al.; *Int. J. Cancer*, **121**, 2801 (2007).



$C_{47}H_{90}N_2O_2=715.23$

Appearance: Yellow Oily matter

| Description | Wako Cat. No. (Pkg. Size) | Note |
|--|---------------------------|--|
| MI-22 [Metastasis Inhibitor-22][N ¹ ,N ¹ ,N ⁷ ,N ⁷ -Tetraethyl-2,6-di((Z)-7-hexadecenyl)-heptanediamide] $C_{47}H_{90}N_2O_2 = 715.23$ | 132-15043 (5 mg) | Keep and Ship at 2~10 °C in a dark place. Filled with inert gas. Please arrange for immediate use after opening. |
| | 136-15041 (200 mg) | |

2. Alkylating Compounds

| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|---|---------------------------|---|---|
| 1,4-Butanediol Dimethanesulfonate [Busulfan] 97.0+% (cGC), CAS No. 55-98-1, $C_6H_{14}O_6S_2 = 246.30$ | 029-09352 (25 g) | Chronic myeloid leukemia | Keep and ship below 25 °C in a dark place |
| Cyclophosphamide Monohydrate 97.0+% (Titration), CAS No. 6055-19-2, $C_7H_{15}Cl_2N_2O_2P \cdot H_2O = 279.10$ | 030-12953 (1 g) | Breast cancer, Ovary cancer, Malignant lymphoma | Keep and ship at 2~10 °C in a dark place |
| | 034-12951 (5 g) | | |
| Dacarbazine 98.0+% (Potentiometric titration) CAS No. 4342-03-4, $C_6H_{10}N_6O = 182.18$ | 047-29951 (200 mg) | Malignant melanoma, Malignant lymphoma | Keep and ship at 2~10 °C in a dark place |
| | 043-29953 (1 g) | | |
| Ifosfamide 98.0+% (HPLC) CAS No. 3778-73-2, $C_7H_{15}Cl_2N_2O_2P = 261.09$ | 090-05401 (50 mg) | Lung cancer, Prostate cancer | Keep and ship below 25 °C in a dark place |
| | 096-05403 (500 mg) | | |
| Melphalan CAS No. 148-82-3, $C_{13}H_{18}Cl_2N_2O_2 = 305.20$ | 135-15251 (100 mg) | Multiple myeloma | Keep and ship below 25 °C in a dark place |
| | 131-15253 (1 g) | | |
| Procarbazine Hydrochloride 98.0+% (potentiometric titration) CAS No. 366-70-1, $C_{12}H_{19}N_3O \cdot HCl = 257.76$ | 161-22581 (100 mg) | Malignant lymphoma | Keep and ship below 25 °C in a dark place |
| | 167-22583 (1 g) | | |

3. Antimetabolic Drugs

| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|---|---------------------------|--|---|
| Carmofur CAS No. 61422-45-5, $C_{11}H_{16}FN_3O_3 = 257.26$ | 035-20051 (1 g) | Digestive organs cancer, Breast cancer | Keep and ship at 2~10 °C in a dark place |
| | 031-20053 (5 g) | | |
| Cytosine-1-β-D(+)-arabinofuranoside [Cytarabine] 98.0+% (HPLC), CAS No. 147-94-4, $C_9H_{13}N_3O_5 = 243.22$ | 030-11951 (100 mg) | Digestive organs cancer, Breast cancer, Acute myelogenous leukemia | Keep and ship at 2~10 °C in a dark place |
| | 034-11954 (500 mg) | | |
| | 036-11953 (1 g) | | |
| Doxifluridine CAS No. 3094-09-5, $C_9H_{11}FN_2O_5 = 246.19$ | 042-29901 (100 mg) | Digestive organs cancer, Breast cancer | Keep and ship below 25 °C in a dark place |
| | 048-29903 (1 g) | | |
| 5-Fluorouracil [5-FU] 98.5+% (HPLC) CAS No. 51-21-8, $C_4H_5FN_2O_2 = 130.08$ | 068-01401 (1 g) | Breast cancer, Womb cancer, Digestive organs cancer | Keep and ship at RT in a dark place |
| | 064-01403 (5 g) | | |
| | 066-01402 (25 g) | | |
| Hydroxyurea [Hydroxycarbamide] 90.0+% (Titration) CAS No. 127-07-1, $H_2NCONHOH = 76.06$ | 085-06653 (5 g) | Chronic myeloid leukemia | Keep and ship at 2~10 °C in a dark place |
| | 089-06651 (10 g) | | |
| 6-Mercaptopurine Monohydrate 98.0~102.0% CAS No. 6112-76-1, $C_5H_4N_4S \cdot H_2O = 170.19$ | 130-07991 (1 g) | Acute myelogenous leukemia, Chronic myeloid leukemia | Keep and ship at RT in a dark place |
| | 136-07993 (5 g) | | |
| Methotrexate 98.0+% (HPLC) CAS No. 59-05-2, $C_{20}H_{22}N_6O_5 = 454.44$ | 139-13571 (100 mg) | Breast cancer, Chronic lymphoid leukemia | Keep and ship at RT in a dark place |
| | 135-13573 (1 g) | | |
| 1-(2-Tetrahydrofuryl)-5-fluorouracil [Tegafur] 98.0+% (Titration), CAS No. 17902-23-7, $C_8H_9FN_3O_3 = 200.17$ | 206-10351 (1 g) | Digestive organs cancer, Breast cancer | Keep and ship below 25 °C in a dark place |
| | 202-10353 (5 g) | | |

4. Antibiotics

| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|---|------------------------------|--|--|
| Aclarubicin Hydrochloride Potency: 860+ μ g/mg CAS No. 75443-99-1, $C_{42}H_{53}NO_{15} \cdot HCl = 843.34$ | 017-12341 (10 mg) | Digestive organs cancer, Breast cancer | Keep at 2~10 °C in a dark place and ship at RT |
| Actinomycin D 97.0+% (HPLC) CAS No. 50-76-0, $C_{62}H_{86}N_{12}O_{16} = 1255.42$ | 013-13421 (5 mg) | Wilms' tumor, Trophoblastic disease | Keep and ship at -20 °C in a dark place |
| Bleomycin Hydrochloride Potency: 1,400~2,000 μ g/mg CAS No. 67763-87-5, Molecular formula: Unspecified. | 028-07801 (10 mg) | Skin cancer, Head and neck cancer | Keep at 2~10 °C in a dark place and ship at RT |
| Daunorubicin Hydrochloride CAS No. 23541-50-6, $C_{27}H_{29}NO_{10} \cdot HCl = 563.98$ | 043-30041 (5 mg) | Acute leukemia | Keep and ship at 2~10 °C in a dark place |
| | 049-30043 (50 mg) | | |
| Doxorubicin Hydrochloride [Adriamycin HCl] Potency: 900+ μ g/mg CAS No. 25316-40-9, $C_{27}H_{29}NO_{11} \cdot HCl = 579.98$ | 040-21521 (10 mg) | Digestive organs cancer, Malignant lymphoma | Keep at 2~10 °C in a dark place and ship at RT |
| | 046-21523 (50 mg) | | |
| Epirubicin Hydrochloride CAS No. 56390-09-1, $C_{27}H_{29}NO_{11} \cdot HCl = 579.98$ | 058-07561 (1 mg) | Malignant lymphoma, Digestive organs cancer | Keep and ship at 2~10 °C in a dark place |
| | 054-07563 (5 mg) | | |
| Fumagillin 95+% (TLC), CAS No. 23110-15-8, $C_{26}H_{34}O_7 = 458.54$ | 065-04071 (1 mg) | Antiangiogenic | Keep and ship at -20 °C in a dark place |
| | 061-04073 (5 mg) | | |
| Mitomycin C Potency: 850+ μ g/mg CAS No. 50-07-7, $C_{15}H_{18}N_4O_5 = 334.33$ | 134-07911 (10 mg) | Digestive organs cancer, Womb cancer | Keep at 2~10 °C in a dark place and ship at RT |
| Mitomycin C with NaCl <Mitomycin: 2 mg; NaCl: 48 mg> CAS No. 50-07-7, $C_{15}H_{18}N_4O_5 = 334.33$ | 132-13201 (2 mg) | | |
| | 138-13203 (2 mg \times 10) | | |
| Peplomycin Sulfate Potency: 843+ μ g/mg CAS No. 70384-29-1, $C_{61}H_{88}N_{18}O_{21}S_2 \cdot H_2SO_4 = 1,571.68$ | 169-12011 (10 mg) | Skin cancer, Head and neck cancer | Keep at 2~10 °C in a dark place and ship at RT |
| Pirarubicin Potency: 950+ μ g/mg CAS No. 72496-41-4, $C_{32}H_{37}NO_{12} = 627.64$ | 160-14741 (25 mg) | Breast cancer, Head and neck cancer | Keep at 2~10 °C in a dark place and ship at RT |

5. Plant Alkaloids

| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|---|---------------------------|---|---|
| Paclitaxel 97.0+% (HPLC) CAS No. 33069-62-4, $C_{47}H_{51}NO_{14} = 853.91$ | 169-18616 (1 mg) | Ovary cancer, Stomach cancer, Breast cancer, Digestive organs cancer | Keep and ship at 2~10 °C in a dark place. |
| | 169-18611 (5 mg) | | |
| | 165-18613 (25 mg) | | |
| | 163-18614 (100 mg) | | |
| Vinblastine Sulfate 97.0+% (HPLC) CAS No. 143-67-9, $C_{46}H_{58}N_4O_9 \cdot H_2SO_4 = 909.05$ | 221-00751 (10 mg) | Malignant lymphoma, Trophoblastic disease | Keep and ship at 2~10 °C in a dark place. |
| | 227-00753 (50 mg) | | |
| Vindesine Sulfate 96.0+% (HPLC) CAS No. 59917-39-4, $C_{43}H_{55}N_5O_7 \cdot H_2SO_4 = 852.00$ | 225-01631 (2 mg) | Lung cancer, Gullet cancer | Keep and ship at -80 °C in a dark place. |
| | 221-01633 (10 mg) | | |
| Vinorelbine Ditartrate CAS No. 125317-39-7, $C_{45}H_{54}N_4O_8 \cdot 2C_4H_6O_6 = 1,079.11$ | 222-01641 (10 mg) | Lung cancer, Breast cancer | Keep and ship at -20 °C in a dark place. Filled with inert gas |
| | 228-01643 (50 mg) | | |

6. Synthetic Hormone Agents

| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|--|---------------------------|--------------------------------------|---|
| Cholormadinone Acetate 98.0+% (HPLC) CAS No. 302-22-7, $C_{23}H_{29}ClO_4 = 404.93$ | 035-15161 (1 g) | Prostate dilation syndrome | Keep and ship at RT in a dark place |
| | 031-15163 (5 g) | | |
| Dexamethasone 98.0~102.0% (Titration) CAS No. 50-02-2, $C_{22}H_{29}FO_5 = 392.46$ | 047-18863 (100 mg) | Malignant lymphoma, Breast cancer | Keep and ship at 2~10 °C in a dark place |
| | 041-18861 (1 g) | | |
| Flutamide 98.0+% (HPLC) CAS No. 13311-84-7, $C_{11}H_{11}F_3N_2O_3 = 276.21$ | 069-04851 (2 g) | Prostate cancer | Keep and ship below 25 °C in a dark place |
| | 065-04853 (10 g) | | |
| Medroxyprogesterone Acetate 98.0+% (HPLC) CAS No. 71-58-9, $C_{24}H_{34}O_4 = 386.52$ | 138-09991 (1 g) | Breast cancer, Womb cancer | Keep and ship at RT in a dark place |
| | 134-09993 (5 g) | | |
| Prednisolone 97.0~103.0% (Absorptiometry) CAS No. 50-24-8, $C_{21}H_{28}O_5 = 360.45$ | 165-11491 (1 g) | Malignant lymphoma, Breast cancer | Keep and ship at RT in a dark place |
| | 161-11493 (5 g) | | |
| Tamoxifen Citrate 98.0+% (Titration) CAS No. 54965-24-1, $C_{26}H_{29}NO \cdot C_6H_8O_7 = 563.64$ | 209-14361 (250 mg) | Breast cancer | Keep and ship at 2~10 °C in a dark place. |
| | 205-14363 (1 g) | | |
| | 203-14364 (5 g) | | |
| | 207-14362 (25 g) | | |

7. Platinum Complex

| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|--|---------------------------|---|---|
| Carboplatin 97.0+% (HPLC) CAS No. 41575-94-4, $C_6H_{12}N_2O_4Pt = 371.25$ | 039-16041 (25 mg) | Head and neck cancer, Lung cancer | Keep and ship at RT in a dark place |
| | 035-16043 (250 mg) | | |
| Cisplatin 98.0+% (HPLC) CAS No. 15663-27-1, $PtCl_2(NH_3)_2 = 300.05$ | 033-20091 (200 mg) | Bladder cancer, Head and neck cancer | Keep and ship at 2~10 °C in a dark place. Filled with inert gas |
| | 039-20093 (2 g) | | |
| Oxaliplatin 97.0+% (HPLC) CAS No. 61825-94-3, $C_8H_{14}N_2O_4Pt = 397.29$ | 156-02691 (5 mg) | Colon cancer | Keep and ship at -20 °C in a dark place |
| | 152-02693 (50 mg) | | |

8. Immunostimulant

| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|--|---------------------------|-----------------------------|---|
| Bestatin 96.0+% (HPLC) $C_{16}H_{24}N_2O_4 = 308.37$ | 027-14101 (100 mg) | nonspecific immunostimulant | Keep and ship at -20 °C in a dark place |

9. Others

| Description | Wako Cat. No. (Pkg. Size) | Target Cancer | Note |
|--|---------------------------|----------------------------|---|
| all-trans-Retinoic Acid [Tretinoin] 97.0+% (HPLC) CAS No. 302-79-4, $C_{20}H_{28}O_2 = 300.44$ | 186-01114 (50 mg) | Acute myelogenous leukemia | Keep and ship at -20 °C in a dark place |
| | 182-01116 (100 mg) | | |
| | 182-01111 (250 mg) | | |
| | 188-01113 (1 g) | | |

C. Research for Biological Defense Mechanism

1. LPS (Lipopolysaccharide)

LPS is the component of the outermost layer of the cell wall of Gram-negative bacteria. Two kinds of products, one prepared by isolating rough LPS from cells by phenol-water extraction (Westphal method) (product purified by phenol extraction) and the other purified by ultracentrifugation and washed twice (product purified by ultracentrifugation), are available. These can be used for studies on the induction of various inflammatory responses.

Three LPSs of *Proteus vulgaris* strains are used for serodiagnosis (Weil-Felix reaction) of rickettsial infections (anthrax, epidemic typhus, trombiculiasis). It has been revealed that the LPS O-antigens of *Rickettsias* and *Proteus vulgaris* have a consensus structure.

| Description | strain | purification | Wako Cat. No. (Pkg. Size) | Grade | Storage |
|---|--------|------------------------|---------------------------|-----------------|--------------------------|
| Lipopolysaccharide, from <i>Escherichia coli</i> [LPS], Lyophilized | O26 | by phenol extraction | 120-05131 (25 mg) | for Cellbiology | Ship and keep at 2-10 °C |
| | O55 | by phenol extraction | 127-05141 (25 mg) | | |
| | O111 | by phenol extraction | 125-05201 (25 mg) | | |
| | O127 | by phenol extraction | 124-05151 (25 mg) | | |
| | O26 | by ultracentrifugation | 121-05161 (5 mg) | | |
| | O55 | by ultracentrifugation | 128-05171 (5 mg) | | |
| | O103 | by ultracentrifugation | 126-05471 (5 mg) | | |
| | O111 | by ultracentrifugation | 125-05181 (5 mg) | | |
| | O127 | by ultracentrifugation | 122-05191 (5 mg) | | |
| | O157 | by ultracentrifugation | 129-05461 (5 mg) | | |
| Lipopolysaccharide, from <i>Proteus vulgaris</i> [LPS], Lyophilized | OX2 | by phenol extraction | 124-05271 (25 mg) | | |
| | OX19 | by phenol extraction | 121-05281 (25 mg) | | |
| | OXK | by phenol extraction | 128-05291 (25 mg) | | |

1. Recombinant Protein expressed in PLANTS containing No Animal-derived Components

Culture media without animal by-products have been attracting attention in tissue cultures for regenerative medicine and in the manufacturing of vaccines or antibody drugs with cultured animal cells, etc.

In order to respond to these needs, Wako provides four kinds of recombinant proteins expressed in plants, namely bovine aprotinin, human lactoferrin, human lysozyme and bovine trypsin. These products are free from contamination of viruses of human origin or BSE causative substances.


Aprotinin, Bovine, recombinant, expressed in Plants, Solution

This product is used for the inactivation of trypsin by adding it after trypsinization of adherent cultured animal cells.

Protease inhibitory activity: > 5TIU/mg protein


1 TIU (Trypsin Inhibitor Unit) \approx 900 KIU (Kallikrein Inhibitor Unit)

8 UIP (Peptidases Inhibitor Units) = 1 KIU (Kallikrein Inhibitor Unit)



Lactoferrin, Human, recombinant, expressed in Plants


This product is used suitably for the cultivation of general cells or cells with low growth efficiency, and for the production of IgG₁ from hybridomas. IgG₁ production from hybridomas in the serum-free minimal medium is about 1.5 times higher than in the transferrin-added media.



Lysozyme, Human, recombinant, expressed in Plants

This product exhibits over 4 times higher bacteriolytic activity against Gram positive and negative bacteria when compared to Lysozyme from chicken egg white. The bacteriolytic activity is comparable with Lysozyme of human origin. It is used optimally for the prevention of contamination when producing recombinant proteins from animal cells.

Unit definition: One unit is defined as the amount of enzyme that will cause a change in absorbance of 0.001 at 450 nm using a suspension of *Micrococcus* bacteria as substrate.



Trypsin, Bovine, recombinant, expressed in Corn

This product is used for the trypsinization of adherent cultured animal cells.

Activity: \geq 72 TAME units/mg (\geq 3,300 USP units/mg)

Unit definition: One TAME unit is defined as the amount of enzyme that will catalyze the hydrolysis of 1 μ mol *N* _{α} -*p*-tosyl-L-arginine methyl ester (TAME) per minute in the presence of 0.01 mol/L calcium ion at 25 °C, pH 8.2.

1 TAME unit = 19.2 USP unit = 57.5 BAEE unit


| Description | Wako Cat. No. (Pkg. Size) | Grade | Storage |
|--|---------------------------|------------------|--------------------------|
| Aprotinin , Bovine, recombinant expressed in plants, Solution | 014-21021 (500 μ L) | for Cell Culture | Ship and keep at 2-10 °C |
| | 010-21023 (1,000 μ L) | | |
| | 188-02051 (50 mg) | | |
| Lactoferrin , Human, recombinant expressed in plants [rhLF] | 184-02053 (100 mg) | | |
| | 182-02054 (500 mg) | | |
| | 185-02061 (10 mg) | | |
| Lysozyme , Human, recombinant expressed in plants | 181-02063 (100 mg) | for Cellbiology | Ship and keep at -20 °C |
| | 189-02064 (500 mg) | | |
| | 208-15931 (5 mg) | | |
| Trypsin , Bovine, recombinant expressed in corn | 204-15933 (50 mg) | for Cell Culture | |
| | 018-21541 (1 g) | | |
| Albumin , Human, recombinant expressed in plants | 014-21543 (5 g) | for Cell Culture | |
| | 016-21542 (25 g) | | |

Coming Soon!




Glutamate Receptor Substances

| Ionotropic Receptors | |
|---------------------------------|--|
| NMDA Selective | |
| NMDA Site >> | DL-2-Amino-5-phosphonovaleric Acid, Dextromethorphan Hydrobromide Monohydrate, D-Glutamic Acid, L-Glutamic Acid, DL-Glutamic Acid Monohydrate, (±)-Ibotenic Acid, N-Methyl-D-aspartic Acid |
| Glycine Site >> | D-Cycloserine, Glycine, D-Serine |
| Polyamine Site >> | Ifenprodil Tartrate, Spermidine, Spermine |
| Ion Channel >> | (+)-MK 801 Maleate |
| AMPA / Kainate Selective | |
| AMPA Selective >> | AMPA, Joro Spider Toxin, Quisqualic Acid |
| Kainate Selective >> | Kainic Acid n-Hydrate |
| AMPA / Kainate Selective >> | CNQX disodium Salt, DNQX, NBQX |
| Metabotropic Receptors | |
| | DL-α-(3,5-Dihydroxyphenyl)glycine, (±)-Ibotenic Acid, (±)-α-Methyl-4-carboxyphenylglycine, 2-Methyl-6-(phenylethynyl)pyridine Hydrochloride |

Alphabetically by product name

| | Description | Wako Cat. No. | Note | Grade |
|---|--|---|-------------------------------|--------------------|
| AMPA Selective AMPA receptor agonist | (±)-α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic Acid [AMPA] CAS No. 74341-63-2, C ₇ H ₁₀ N ₂ O ₄ =186.17 | 012-18491 (5mg) | 2~10 °C | for Biochemistry |
| NMDA Selective NMDA receptor antagonist | DL-2-Amino-5-phosphonovaleric Acid [DL-AP5] CAS No. 76326-31-3, C ₅ H ₉ NO ₅ P=197.13 | 018-18471 (10mg) | RT* | for Biochemistry |
| AMPA/Kainate Selective AMPA/Kainate receptor antagonist | CNQX Disodium Salt n-Hydrate , 98.0+% (HPLC) C ₉ H ₂ N ₄ Na ₂ O ₄ | 034-20381 (10mg) | 2~10 °C | for Cellbiology |
| NMDA Selective Glycine site agonist | D-Cycloserine CAS No. 68-41-7, C ₃ H ₆ N ₂ O ₂ =102.09 | 032-12631 (1g) 038-12633 (5g) | -20 °C | for Biochemistry |
| NMDA Selective NMDA receptor antagonist | Dextromethorphan Hydrobromide Monohydrate , 98.0+% (Titration) CAS No. 6700-34-1, C ₁₈ H ₂₅ NO·HBr·H ₂ O=370.33 | 041-21551 (5g) 049-21552 (25g) | below 25 °C | for Biochemistry |
| Metabotropic receptor group1(mGlu1, mGlu5) agonist | DL-α-(3,5-Dihydroxyphenyl)glycine [DL-3,5-DHPG] CAS No. 146255-66-5, C ₈ H ₉ NO ₄ =183.16 | 043-24671 (100mg) | Keep at 2~10 °C Ship at RT | for Biochemistry |
| AMPA/Kainate Selective AMPA/Kainate receptor antagonist | DNQX [6,7-Dinitroquinoxaline-2,3-dione], 95.0+% (TLC) CAS No. 2379-57-9, C ₆ H ₄ N ₄ O ₆ =252.14 | 040-26303 (10mg) 044-26301 (50mg) | -20 °C | for Biochemistry |
| NMDA Selective NMDA receptor agonist | D-Glutamic Acid , 99.0+% (Titration) CAS No. 6893-26-1, C ₅ H ₉ NO ₄ =147.13 | 075-00493 (1g) 077-00492 (25g) | RT | Wako Special Grade |
| | L-Glutamic Acid , 99.0+% (Titration) CAS No. 56-86-0, C ₅ H ₉ NO ₄ =147.13 | 070-00502 (25g) 072-00501 (100g) 074-00505 (500g) | RT | JIS Special Grade |
| | DL-Glutamic Acid Monohydrate , 97.0+% (Titration) CAS No. 19285-83-7, C ₆ H ₉ NO ₄ ·H ₂ O=165.15 | 074-02102 (25g) | RT | Wako Special Grade |
| NMDA Selective Glycine site agonist | Glycine , 99.0+% (Titration) CAS No. 56-40-6, H ₂ NCH ₂ COOH=75.07 | 073-00732 (25g) 075-00731 (100g) 077-00735 (500g) | RT | JIS Special Grade |
| NMDA agonist Metabotropic Receptor Non-selective mGlu agonist | (±)-Ibotenic Acid CAS No. 2552-55-8, C ₅ H ₆ N ₂ O ₄ =158.11 | 098-04721 (5mg) | RT | for Biochemistry |
| NMDA Selective Polyamine Site | Ifenprodil Tartrate , 98.5+% (Titration) CAS No. 23210-58-4, (C ₂₁ H ₂₇ NO ₂) ₂ ·C ₄ H ₆ O ₆ =800.98 | 099-03911 (100mg) | RT | for Biochemistry |
| AMPA Selective AMPA receptor antagonist | Joro Spider Toxin [JSTX-3] CAS No. 112163-33-4, C ₂₇ H ₄₇ N ₇ O ₆ =565.71 | 104-00051 (0.1mg) | 2~10 °C | for Biochemistry |
| Kainate Selective Kainate receptor agonist | Kainic Acid n-Hydrate , 98.0+% (HPLC) C ₁₀ H ₁₃ NO ₄ ·nH ₂ O=213.23  | 118-00751 (10mg) | 2~10 °C | for Biochemistry |
| | It is an amino acid with glutamate skeleton isolated from one of red algae, Digenea (Corsican weed, <i>Digenea simplex</i>) known as an ascaricide. This product is one of selective agonist for kainate-type glutamate receptor and has a potent CNS stimulating effect. It is used for studies on the signal transduction system via kainate cascade, neuronal apoptosis, ALS (amyotrophic lateral sclerosis), and pathological mechanism of Alzheimer disease. Appearance of solution: Clear | | | |

Glutamate Receptor Substances ~continued~

| | Description | Wako Cat. No. | Note | Grade |
|---|---|---|---------|-----------------------|
| Metabotropic Receptor group1(mGlu1, mGlu5), group2(mGlu2, mGlu3) antagonist | (±)-MCPG [(±)-α-Methyl-4-carboxyphenylglycine] 99.0+% (HPLC) CAS No. 146669-29-6; C ₁₀ H ₁₁ NO ₄ =209.20  | 137-15571 (10mg) 133-15573 (50mg) | 2~10 °C | for Cellbiology |
| NMDA Selective ion channel Non-competitive NMDA receptor antagonist | (+)-MK 801 Maleate [Dizocilpine Maleate] , 98.0+% (HPLC) CAS No. 77086-22-7; C ₁₆ H ₁₅ N.C ₄ H ₄ O ₄ =337.37 Acts by binding to a site located within the NMDA associated ion channel  • C ₄ H ₄ O ₄ | 134-15461 (10mg) 130-15463 (50mg) | 2~10 °C | for Cellbiology |
| Metabotropic Receptor Metabotropic receptor mGlu ₅ Non-competitive antagonist at mGlu5 receptor subtype | MPEP Hydrochloride , 98.0+% (HPLC) [2-Methyl-6-(phenylethynyl)pyridine Hydrochloride], C ₁₄ H ₁₁ N.HCl=229.70  • HCl | 131-15471 (10mg) | 2~10 °C | for Cellbiology |
| AMPA/Kainate Selective AMPA/Kainate receptor antagonist | NBQX [6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3- dione], 99+% (TLC) CAS No. 118876-58-7, C ₁₂ H ₈ N ₄ O ₆ S=336.28 | 148-06751 (10mg) | 2~10 °C | for Biochemistry |
| NMDA Selective NMDA receptor agonist | N-Methyl-D-aspartic Acid [NMDA] CAS No. 6384-92-5, C ₅ H ₉ NO ₄ =147.13 | 132-13681 (50mg) | RT | for Biochemistry |
| NMDA Selective Glycine site agonist | D-Serine , 99.0+% (Titration) CAS No. 312-84-5, HOCH ₂ CH(NH ₂)COOH | 191-08821 (1g) 197-08823 (5g) 199-08822 (25g) | RT | Wako Special Grade |
| AMPA Selective Metabotropic Receptor Group1 (mGlu1, mGlu5) agonist | Quisqualic Acid CAS No. 52809-07-1, C ₅ H ₇ N ₃ O ₅ =189.13 | 174-00531 (5mg) | 2~10 °C | for Biochemistry |
| NMDA Selective Polyamine site agonist | Spermidine , 95.0+% (Titration) CAS No. 124-20-9, H ₂ N(CH ₂) ₄ NH(CH ₂) ₃ NH ₂ =145.25 | 195-09821 (1g) 191-09823 (5g) | 2~10 °C | for Biochemistry |
| NMDA Selective Polyamine site | Spermine , 95.0+% (Titration) CAS No. 71-44-3, C ₁₀ H ₂₆ N ₄ =202.34 Acts as an agonist during depolarization and as an antagonist during hyperpolarization. | 198-09811 (250mg) 194-09813 (1g) | 2~10 °C | for Biochemistry |

* RT: room temperature

LabAssay™ is an ELISA kit for simultaneous measurement of multi animal-samples using a microplate as well as measurement using test tubes.

Research Use Only

| # | Category | Detection | Product Name | Wako Catalog No. | Pkg. Size | Grade |
|---|---|--------------|------------------------|------------------|-------------|-----------------|
| 1 | Lipid | Triglyceride | LabAssay™ Triglyceride | 290-63701 | 1,000 tests | for Cellbiology |
| 2 | Enzyme | ALP | LabAssay™ ALP | 291-58601 | 900 tests | |
| 3 | Protein & nonprotein nitrogen compounds | A/G | LabAssay™ A/G | 292-63901 | 1,000 tests | |
| | | Creatinin | LabAssay™ Creatinin* | 290-65901 | 500 tests | |
| 4 | Sugar | Uric Acid | LabAssay™ Uric Acid | 292-64001 | 1,300 tests | |
| | | Glucose | LabAssay™ Glucose | 298-65701 | 1,000 tests | |

* : Not available for sale in Europe.

1. Lipid

LabAssay™ Triglyceride (GPO • DAOS method)

Lipids in serum consist of triglycerides, cholesterol, phospholipids, free fatty acids and slight amounts of fat-soluble components such as fat-soluble vitamins and carotenes. Triglycerides, as major components of very low density lipoprotein (VLDL) and chylomicrons, play an important role in metabolism as energy sources and transporters of dietary fat.

This kit is based on an enzymatic method using N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline sodium salt (DAOS) as a blue pigment.

[Performance]

(1) Sensitivity (Absorbance):


Purified water: max. 0.10 / 300mg/dL triglyceride sample: 0.09 ~ 0.25

(2) Specificity (Triglyceride Concentration):

A known concentration of control serum: within ±12%

[Reference] 1) Spayd, R. W., Bruschi, B., et al.: *Clin. Chem.*, 24, 1343 (1978).

[Standard Curve]



| Description | Wako Cat. No. (Pkg. Size) | Grade | Note |
|--|---------------------------|-----------------|--------------------------|
| LabAssay™ Triglyceride (GPO • DAOS method) | 290-63701 (1,000 tests) | for Cellbiology | Keep and ship at 2~10 °C |
| [Kit Contents] | | | |
| 1. Buffer: | 3 vials × for 105 mL | | |
| 2. Chromogen Substrate: | 3 vials × for 105 mL | | |
| 3. Standard Solution: | 1 vial × 10 mL | | |

2. Enzymes

LabAssay™ ALP (Alkaline Phosphatase activity assay with p-Nitrophenylphosphate as a substrate)

Alkaline Phosphatase (ALP) is distributed in a variety of tissues such as liver, bone, and small intestine in animals. The change of the enzyme activity in tissues is an important hallmark for physiological phenomena as osteogenesis and so on.

This kit is for Alkaline Phosphatase assay in a simultaneous multi-sample assay format with a microplate using p-Nitrophenylphosphate as a substrate.


[Performance]

<Dynamic Assay Range> above 0.06 mmol/L

<Standard Assay Range> 0 ~ 0.5 mmol/L, <Reproducibility> C.V. below 10 %

[Reference] 1) Yamamoto, M., Takahashi, Y., Tabata, Y.: *Biomaterials*.24 (24), 4375 (2003).

[Standard Curve]



| Description | Wako Cat. No. (Pkg. Size) | Grade | Note |
|---|---------------------------|-----------------|--------------------------|
| LabAssay™ ALP | 291-58601 (900 tests) | for Cellbiology | Keep and ship at 2~10 °C |
| [Kit Contents] | | | |
| 1. Substrate Tablet (p-Nitrophenylphosphate Disodium 6.7 mmol/L, after dissolving): | 20 tablets | | |
| 2. Buffer Solution (2.0 mmol/L MgCl ₂ , 0.1 mol/L Carbonate Buffer, pH 9.8): | 1 vial × 100 mL | | |
| 3. Stop Solution (0.2 mol/L Sodium Hydroxide Solution): | 1 vial × 100 mL | | |
| 4. Standard Solution (0.5 mmol/L p-Nitrophenol Solution): | 1 vial × 10 mL | | |

3. Protein & nonprotein nitrogen compounds

LabAssay™ A/G (BCG method, Biuret method)

Blood serum contains two major protein groups: albumin and globulin. The ratio of albumin to globulin (A/G ratio) is calculated from values obtained by direct measurement of total protein and albumin. It represents the relative amounts of albumin and globulins.

This kit is able to measure total protein in mouse and human serum by the Biuret method and albumin by the BCG (Bromocresol green) method, and furthermore to calculate A/G ratio.

[Performance]

Albumin

(1) Sensitivity (Absorbance):

Purified water: 0.120 ~ 0.220 / Std Serum (5.0 g/dL Alb): 0.480 ~ 0.810

(2) Specificity (albumin concentration):

a known concentration of control serum: within $\pm 12\%$

Total Protein


(1) Sensitivity (Absorbance):

Purified water: 0.050 ~ 0.100 / Std Serum (8.0g/dL Total protein): 0.300 ~ 0.500

(2) Specificity (protein concentration)

a known concentration of control serum: within $\pm 10\%$

[Standard Curve]



[References]

- 1) Dumas, B. T., Watson, W. A. and Biggs, H. G. : *Clin. Chem. Acta.*, **31**, 87 (1971).
- 2) Gornall, A. G., Bardawill, C. J. and David, M. M. : *J. Biol. Chem.*, **177**, 751 (1949).

| Description | Wako Cat. No. (Pkg. Size) | Grade | Note |
|---|--------------------------------|-----------------|--------------------------|
| LabAssay™ A/G (BCG method, Biuret method) | 292-63901 (1,000 tests) | for Cellbiology | Keep and ship at 2~10 °C |
| [Kit Contents] 1. Albumin Chromogen Reagent: 1 vial × 250 mL 2. Total Protein Chromogen Reagent: 1 vial × 250 mL 3. Standard Serum (from Bovine Serum): 1 vial × for 3 mL 4. Albumin Adjustment Buffer: 1 vial × 25 mL | | | |

LabAssay™ Creatinine (Jaffé method)

Creatinine is a breakdown product of creatine phosphate in muscle. It is mainly filtered by the kidneys, though a small amount is actively secreted. LabAssay™ Creatinine is based on an in vitro colorimetric Jaffé method for the quantitative determination of creatinine in mouse serum or urine.

[Performance]


(1) Sensitivity in a test tube (Absorbance):

Purified water: 0.010 ~ 0.020 / 10mg/dL creatinine: 0.400 ~ 0.500

(2) Specificity (Creatinine Concentration):

A known concentration of control serum: within $\pm 10\%$

[Standard Curve]



[References]

- 1) Bonsnes, R. W. and Taussky, H. H.: *J. Biol. Chem.*, **158**, 581(1945).
- 2) Henry, R. J.: *Clinical Chemistry*, 287 (Harper & Row), New York (1966).

| Description | Wako Cat. No. (Pkg. Size) | Grade | Note |
|---|------------------------------|-----------------|--|
| LabAssay™ Creatinine (Jaffé method) | 290-65901 (500 tests) | for Cellbiology | Keep and ship at 2~10 °C in a dark place |
| [Kit Contents] 1. Deproteinizing Reagent: 1 vial × 150 mL (Sodium Tungstate, Phosphoric Acid) 2. Picric Acid Reagent: 1 vial × 50 mL 3. 0.75 mol/L Sodium Hydroxide Solution: 1 vial × 50 mL 4. Standard Solution (Creatinine: 10 mg/dL): 1 vial × 15 mL | | | |

Not available for sale in Europe.

3. Protein & nonprotein nitrogen compounds ~continued~

LabAssay™ Uric Acid (Uricase • TOOS method)

Uric acid is the relatively water-insoluble end product of purine nucleotide metabolism.

This kit is able to measure uric acid in mouse and human serum by an enzyme reaction using N-Ethyl- N- (2-hydroxy-3-sulfopropyl) -3-methylaniline sodium salt (TOOS).

[Performance]

(1) Sensitivity (Absorbance)


Purified water: max. 0.15 / 10 mg/dL Uric Acid: 0.04 ~ 0.26

(2) Specificity (uric acid concentration):

a known concentration of control serum: within ±15%

[Reference]

1) Kabasakalian, P., Kalliney, S. and Westcott, A.: *Clin. Chem.*, **19**, 522-524 (1973).

[Standard Curve]

| Description | Wako Cat. No. (Pkg. Size) | Grade | Note |
|--|--------------------------------|-----------------|--------------------------|
| LabAssay™ Uric Acid (Uricase • TOOS method) | 292-64001 (1,300 tests) | for Cellbiology | Keep and ship at 2~10 °C |
| [Kit Contents] | | | |
| 1. Chromogen: | 4 vials × for 100 mL | | |
| 1. Buffer: | 4 vials × 100 mL | | |
| 1. Standard Solution (Uric acid 10 mg.dL): | 1 vial × 10 mL | | |

4. Sugar

LabAssay™ Glucose (Mutarotase-GOD method)

When a sample is mixed with the Chromogen Reagent, the α -form of glucose in the sample is converted to β -form by mutarotase. β -DGlucose is oxidized and yields hydrogen peroxide by glucose oxidase (GOD). In the presence of peroxidase (POD), the formed hydrogen peroxide yields a red pigment by quantitative oxidation condensation with phenol and 4-aminoantipyrine. The glucose concentration is obtained by measuring absorbance of the red pigment.

[Performance]

(1) Sensitivity (Absorbance):


Purified water: max. 0.03 / 200mg/dL glucose sample: 0.40 ~ 0.55

(2) Specificity (Glucose Concentration):





A known concentration of control serum or urine: within ±12%

[Reference]

1) Miwa, I., Okuda, J., Maeda, K. and Okuda, G.: *Clin. Chim. Acta.*, **37**, 538 (1972).

[Standard Curve]




| Description | Wako Cat. No. (Pkg. Size) | Grade | Note |
|--|--------------------------------|-----------------|--|
| LabAssay™ Glucose (Mutarotase-GOD method) | 298-65701 (1,000 tests) | for Cellbiology | Keep and ship at 2~10 °C in a dark place |
| [Kit Contents] | | | |
| 1. Buffer: | 2 vials × 150 mL | | |
| 2. Chromogen Reagent: | 2 vials × for 150 mL | | |
| 3. Glucose Standard I (200 mg/dL Glucose): | 1 vial × 10 mL | | |
| 4. Glucose Standard II (500 mg/dL Glucose): | 1 vial × 10 mL | | |







| Description | Wako Cat. No. (Pkg. Size) | |
|---|---|--|
| 1. DNA Methylation | | |
| (1) DNA Methylation Inhibitors | | |
| <p>Methylation of DNA contributes to the epigenetic regulation of gene expression. Methylated DNAs are formed by addition of methyl group to the carbon atom at 5-position of C (cytosine) bases in DNA by DNA methyltransferase (DNMT).</p> <p>Two kinds of DNA methylation by DNMT are observed; one is called maintenance DNA methylation by DNMT1 (methylation is maintained after DNA replication), and the other is <i>de novo</i> DNA methylation by DNMT3a and DNMT3b (new methylation occurs in unmethylated DNA). Since the amount of methylated DNA changes depending on the types of cancer and germ cells or cell cycle, gene expression can be analyzed in detail by effective inhibition of DNA methylation.</p> | | |
| <p>5-Azacytidine, 98.0+% (HPLC) $C_8H_{12}N_4O_5 = 244.20$, CAS No. 320-67-2 for Biochemistry, Keep and ship at $-20^{\circ}C$</p> <p>This product is one of the DNA methylation inhibitors that induce demethylation of genomic DNA in a concentration-dependent way¹⁾. It is used for researches on methylation of the promoter site in prostatic cancer cells²⁾.</p> | <p>016-16711 (50 mg) 012-16713 (250 mg) 010-16714 (1 g)</p> | <p>[References]</p> <ol style="list-style-type: none"> 1) Stresemann, C., et al.: <i>Cancer Res.</i>, 66, 2794 (2006). 2) Leiblich, A., et al.: <i>Oncogene.</i>, 25, 2953 (2006). 3) Bowers R.R., et al.: <i>PNAS.</i>, 103, 13022 (2006). 4) Cheng C., et al.: <i>Mol. Genet. Genomics</i>, 276, 378 (2006).  |
| <p>5-Aza-2'-deoxycytidine, 97.0+% (HPLC) $C_8H_{12}N_4O_4 = 228.21$, CAS No. 2353-33-5 for Genetic Research, Keep and ship at $-20^{\circ}C$</p> <p>This product is one of the cytidine analog DNA methylation inhibitors that induce demethylation of genomic DNA in a concentration-dependent way¹⁾. It is used for researches on methylation of the promoter site in lung cancer cells²⁾.</p> | <p>018-20941 (10 mg) 014-20943 (50 mg)</p> | <p>[References]</p> <ol style="list-style-type: none"> 1) Stresemann, C., et al.: <i>Cancer Res.</i>, 66, 2794 (2006). 2) Vuilleminot, B.R., et al.: <i>Mol. Cancer Res.</i>, 4, 267 (2006) 3) Kim T.Y., et al.: <i>Cancer Res.</i>, 66, 7490 (2006). 4) Fulda S., et al.: <i>Oncogene</i>, 25, 5125 (2006).  |
| <p>DNA Methyltransferase Inhibitor, 97.0+% (HPLC) $C_{19}H_{14}N_2O_4 = 334.33$ for Genetic Research, Keep and Ship at $-20^{\circ}C$</p> <p>This product inactivates DNA methyltransferase activity by binding to its active center unlike 5-azacytidine or 5-aza-2'-deoxycytidine.</p> | <p>041-30101 (10 mg) 047-30103 (25 mg)</p> | <p>[References]</p> <ol style="list-style-type: none"> 1) Stresemann, C., et al.: <i>Cancer Res.</i>, 65, 6305 (2005).  |
| <p>(-)-Epigallocatechin Gallate, 90.0+% (HPLC) for Biochemistry, Keep at $2\sim 10^{\circ}C$ and ship at RT $C_{22}H_{18}O_{11} = 458.37$, CAS No. 989-51-5</p> | <p>059-05411 (100 mg)</p> | <p>Polyphenol: Catechin from green tea extracts Solubility: Soluble in methanol (10 g/L methanol soln.)</p> |
| <p>Procaine Hydrochloride, 99.0+% (Titration) for Biochemistry, Keep and ship at RT $C_{13}H_{20}N_2O_2 \cdot HCl = 272.77$, CAS No. 51-05-8</p> | <p>167-15111 (50 g)</p> | <p>Solubility: Freely soluble in water, soluble in ethanol and sparklingly soluble in chloroform</p> |
| <p>Zebularine, 97.0+% (HPLC) $C_9H_{12}N_2O_5 = 228.20$ for Genetic Research, Keep and ship and $4^{\circ}C$</p> <p>This product is one of the cytidine analog DNA methylation inhibitors that induce demethylation of genomic DNA in a concentration-dependent way¹⁾. It is known to be highly stable in solution and to have low toxicity²⁾.</p> | <p>267-01891 (5 mg) 263-01893 (25 mg)</p> | <p>[References]</p> <ol style="list-style-type: none"> 1) Stresemann, C., et al.: <i>Cancer Res.</i>, 66, 2794 (2006). 2) Cheng, J.C., et al.: <i>J. Natl. Cancer Inst.</i>, 95, 399 (2003). 3) Dote H., et al.: <i>Clin. Cancer Res.</i>, 11, 4571 (2005). 4) Hodge D.R., et al.: <i>Cancer Res.</i>, 65, 4673 (2005).  |
| (2) Detection of Cell Proliferation | | |
| <p>5-Bromo-2'-deoxyuridine, [5-BrdU], 98.0+% (HPLC) for Biochemistry, Keep and ship at $-20^{\circ}C$ $C_9H_{11}BrN_2O_5 = 307.10$, CAS No. 59-14-3</p> | <p>027-15561 (1 g) 023-15563 (5 g)</p> | |

| Description | Wako Cat. No. (Pkg. Size) | |
|---|--------------------------------------|---|
| 1. DNA Methylation ~continued~ | | |
| (3) Modified Nucleotides | | |
| Modified nucleotide triphosphates for epigenetics research, which are applicable to PCR, are available. | | |
| 2'-Deoxyinosine 5'-Triphosphate Solution [dITP Solution], 98+% for Molecular Biology, Keep and ship at -20°C CAS No. 95648-77-4 | 048-29861 (25 μmol (100 mM)) | pH: approximately 7 |
| 5-Hydroxymethyl-2'-deoxycytidine 5'-Triphosphate Soln. [HMdCTP Solution], 98+% for Genetic Research, Keep and ship at -20°C | 083-08371 (25 μmol (100 mM)) | pH: approximately 7 |
| 5-Methyl-2'-deoxycytidine 5'-Triphosphate Soln. [dm5CTP Solution], 95+% (HPLC) for Genetic Research, Keep and ship at -20°C CAS No. 838-07-3 | 049-29891 (1 μmol (10 mM)) | |
| N⁴-Methyl-2'-deoxycytidine 5'-Triphosphate Solution [dm4CTP Solution], 95+% (HPLC) for Genetic Research, Keep and ship at -20°C | 042-29881 (1 μmol (10 mM)) | |
| N⁶-Methyl-2'-deoxyadenosine 5'-Triphosphate Solution , 95.0+% (HPLC) [dm6ATP Solution] for Genetic Research, Keep and ship at -20°C | 045-29871 (1 μmol (10 mM)) | |
| (4) Others | | |
| Anti 5-Methylcytosine, Monoclonal Antibody for Immunocytochemistry, Keep and ship at -20°C | 015-19721 (100 μL) | Mouse ascites filtrate, Subclass: IgM , Specific to methylcytosine, and reactive with cytosine and thymidine at less than 1%. Working dilution: Westernblot (1:1,000~1:10,000); Immunofluorescence (1:100) |
| Micrococcal Nuclease, lyophilized for Genetic Research, Keep and ship at 2~10°C CAS No. 9013-53-0, EC No. 3.1.31.1, MW: 168,000 | 137-14731 (abt.15,000 units/vial) | Application: Nucleosome modeling experimentation |

2. Cell Cycle and Transcription**(1) Histone Deacetylase (HDAC) Inhibitors**

HDAC plays a central role in chromatin structure formation associated with the nuclear distribution of DNA. HDAC inhibitors show connections with cell division cycles and differentiation, as well as with antitumor activity and apoptosis-inducing activity through the inhibition of the deacetylating activity of HDAC.

| | | |
|---|------------------|--|
| ITSA1 [N-(1H-Benzotriazol-1-yl)-2,4-dichlorobenzamide] for Cellbiology, Keep and ship at 2~10°C C ₁₃ H ₇ Cl ₂ N ₃ O = 292.12 Inhibitor of Trichostatin A | 093-05251 (5 mg) |  |
| M 344 [4-Dimethylamino-N-(6-hydroxycarbonylhexyl)-benzamide] for Cellbiology, Keep and ship at -20°C C ₁₆ H ₂₅ N ₃ O ₃ = 307.39, CAS No. 251456-60-7 Inhibitor of HDAC Class I and II. Structural homologue of Trichostatin A. | 139-14671 (1 mg) |  |
| MC 1293 [3-(4-Toluoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide] for Cellbiology, Keep and ship at -20°C C ₁₆ H ₁₆ N ₂ O ₃ = 284.31 Inhibitor of HDAC1 and maize deacetylase. | 136-14681 (5 mg) |  |


| Description | Wako Cat. No. (Pkg. Size) | |
|--|--|--|
| 2. Cell Cycle and Transcription ~continued~ | | |
| (1) Histone Deacetylase (HDAC) Inhibitors ~continued~ | | |
| Sirtinol [2-[(2-Hydroxynaphthalen-1-ylmethylene)amino]-N-(1-phenethyl)benzamide] for Cellbiology, Keep and ship at -20°C $C_{26}H_{22}N_2O_2 = 394.47$ HDAC Class III Inhibitor. Cell-permeable | 197-13671 (5 mg) |  |
| Splitomicin [1,2-Dihydro-3H-naphtho[2,1-b]-pyran-3-one] for Cellbiology, Keep and ship at 2~10°C $C_{13}H_{10}O_2 = 198.22$, CAS No. 5690-03-9 HDAC Class III Inhibitor. Cell-permeable | 190-13661 (1 mg) |  |
| Trichostatin A for Biochemistry, Keep and ship at -20°C $C_{17}H_{22}N_2O_3 = 302.37$, CAS No. 58880-19-6 Potent & reversible Inhibitor of HDAC Class I & II | 200-11993 (1 mg) 204-11991 (5 mg) |  |
| Valproic Acid for Biochemistry, Keep and ship at RT $C_8H_{16}O_2 = 144.21$, CAS No. 99-66-1 Inhibitor of HDAC1 | 227-01071 (5 g) 225-01072 (25 g) | $\begin{array}{l} H_3C - H_2C - H_2C \\ H_3C - H_2C - H_2C \end{array} \left. \begin{array}{l} \\ \\ \end{array} \right\} CH - CO_2H$ |
| (2) SIRT1 (classified into HDAC Class III) Activators | | |
| Butein [2',4',3,4-Tetrahydroxychalcone], 98.0+% (HPLC) for Biochemistry, Keep and ship at -20°C $C_{15}H_{12}O_5 = 272.25$, CAS No. 487-52-5 a SIRT1 Activator as well as a protein tyrosine kinase inhibitor | 027-14461 (10 mg) | Solubility: Freely soluble in ethanol, soluble in methanol and dimethylsulfoxide. Insoluble in hot water. Powder density: 6 mL/g  |
| Piceatannol [3,4,3',5'-Tetrahydroxy-trans-stibene] for Cellbiology, Keep and ship at 2~10°C $C_{14}H_{12}O_4 = 244.24$, CAS No. 10083-24-6 a SIRT1 Activator as well as a protein tyrosine kinase syk selective inhibitor | 169-21661 (10 mg) |  |
| Resveratrol [trans-3,4',5-Trihydroxystibene], 98.0+% (HPLC) for Biochemistry, Keep and ship at -20°C $C_{14}H_{12}O_3 = 228.24$ SIRT1 Activator as well as COX-1 inhibitor | 185-01721 (100 mg) 181-01723 (500 mg) | Solubility: Soluble in ethanol and acetone. Insoluble in water.  |
| [Reference] Howitz, K.T., et al.: <i>Nature</i> , 425, 191 (2003). | | |

H. Environmentally-sensitive Fluorophore to proteins

Solvent-sensitive Fluorescent Probe

I-SO-IAA

I-SO-IAA is an environmentally-sensitive fluorophore to proteins, which has merocyanine skeleton and iodoacetamide. The fluorescence quantum yield is sharply dependent on solvent polarity or viscosity, enabling them to report changes of fluorescence intensity in their protein environment. Additionally, it can be excited with visible light, unlike other probes.



[Labeling Procedure]

- 1. Preparing Protein Solution**
Dissolve Protein at 50~100 μ mol/L in a suitable buffer such as 10~100mM phosphate, Tris and HEPES at pH 7.0~7.5 and room temperature. Reduce disulfide bonds of the protein with a 10-fold molar excess of DTT.
- 2. Preparing I-SO-IAA Solution**
Dilute I-SO-IAA with DMSO to a final concentration of 10mmol/L (=Stock Solution). Protect it from light as much as possible.
- 3. Labeling the Protein with I-SO-IAA**
Add approximately 2~10 moles of I-SO-IAA for each mole of protein. React for 1 hour at room temperature or overnight at 4°C.

[Reference]

1. Touthkine, A., Kraynov, N. and Hahn, K.: "Solvent-sensitive dyes to report protein conformational changes in living cells", *J. Am. Chem. Soc.*, **125**, 4132 (2003)

| Description | Wako Cat. No. (Pkg. Size) | Grade | Storage |
|--|---------------------------|-----------------|--|
| I-SO-IAA | 093-05371 (5 mg) | for Cellbiology | Ship and keep at -20°C in a dark place |
| 1H-Indole-1-propanesulfonic acid, 2-[(2E,4Z)-4-(1,1-dioxido-3-oxobenzo[b]thien-2(3H)-ylidene)-2-butenylidene]-2,3-dihydro-5-[(iodoacetyl) amino]-3,3-dimethyl-, monosodium salt, (2Z)-(9C1) $C_{27}H_{26}IN_2NaO_7S_2 = 704.53$ [Fluorescence] λ_{ex} : 600 nm; λ_{em} : around 630 nm | | | |

- Listed products are intended for laboratory research use only, and not to be used for drug, food or human use.
- Please visit our online catalog to search for other products from Wako ; <http://www.e-reagent.com>
- This brochure may contain products that cannot be exported to your country due to regulations.
- Bulk quote requests for some products are welcomed. Please contact us.

08116IBK

Wako Pure Chemical Industries, Ltd.

<http://www.wako-chem.co.jp>

1-2, Doshomachi 3-Chome
Chuo-Ku, Osaka 540-8605, Japan
Tel: 81-6-6203-3741
Fax: 81-6-6203-1999

Wako Chemicals USA, Inc.

<http://www.wakousa.com>

Toll-Free (U.S. only): 1-877-714-1920
Head Office (Richmond, VA):
Tel: 1-804-714-1920/ Fax: 1-804-271-7791
Los Angeles Sales Office (Irvine, CA):
Tel: 1-949-679-1700 / Fax: 1-949-679-1701
Boston Sales Office (Cambridge, MA):
Tel: 1-617-354-6772 / Fax: 1-617-354-6774

Wako Chemicals GmbH

<http://www.wako-chemicals.de>

European Office:
Fuggerstraße 12, D-41468
Neuss, Germany
Tel: 49-2131-3111-0
Fax: 49-2131-311100